This volume brings together an international group of clinicians and clinical scientists to contribute to a state-of the-art review of the underlying pathogenic mechanisms, methods of clinical assessment, classification and diagnosis of renal disease, combined with a detailed overview of treatment strategies. An essential reference source for all those involved with the care of patients with renal involvement in systemic autoimmune disease, and for those contributing to research into the underlying pathogenic mechanisms in these disorders.
Inhaltsverzeichnis
1;Cover;1 2;Contents;16 3;Preface;6 4;Series Editor;8 5;Volume Editors;10 6;List of Contributors;12 7;Part I: Introduction;18 7.1;Introduction;20 8;Part II: Pathogenic Mechanisms;38 8.1;Chapter 1. Pathogenesis of Renal Diseases: Autoimmunity;40 8.1.1;1. Introduction;40 8.1.2;2. Mechanisms of tolerance;41 8.1.3;3. Mechanisms of tolerance maintenance;46 8.1.4;4. Emergence of autoimmune renal disease: breakdown of tolerance checkpoints;52 8.1.5;5. Conclusions;55 8.1.6;Key points;57 8.1.7;Further Reading;57 8.2;Chapter 2. Pathogenesis of Renal Disease: Complement;60 8.2.1;1. Introduction;60 8.2.2;2. Complement activation;61 8.2.3;3. Complement regulation;62 8.2.4;4. Human studies of complement and autoimmune renal disease;63 8.2.5;5. Animal studies of the role of complement in renal disease models;64 8.2.6;6. Studies in mice with targeted deletion of complement proteins;68 8.2.7;7. The future of complement and human systemic autoimmune diseases;71 8.2.8;Key points;72 8.2.9;Acknowledgments;73 8.2.10;References;73 8.3;Chapter 3. Pathogenesis of Renal Disease: Cytokines and Other Soluble Factors;80 8.3.1;1. Introduction;80 8.3.2;2. Cytokine regulation and differentiation of adaptive immunity;81 8.3.3;3. Cytokine regulation of renal inflammation in specific autoimmune diseases and their animal models;83 8.3.4;4. ANCA-associated autoimmune vasculitis;85 8.3.5;5. Lupus nephritis;86 8.3.6;6. Targeting cytokines in human autoimmune GN;87 8.3.7;7. Chemokines in autoimmune renal disease;88 8.3.8;8. Soluble microbial products;89 8.3.9;Key points;90 8.3.10;Acknowledgments;91 8.3.11;References;91 8.4;Chapter 4. Pathogenesis of Renal Disease: Cellular Mechanisms;98 8.4.1;1. Introduction;98 8.4.2;2. Overview of immune inflammation;98 8.4.3;3. Activation;99 8.4.4;4. Regulation of immune cell activation;100 8.4.5;5. Immune cells and clinical renal disease;101 8.4.6;6. Immune cells in experimental models of nephritis;102 8.4.7;7. Immune cell function in nephritis;103 8.4.8;8. Characteriz
ation of immune cells within inflamed glomeruli;104 8.4.9;9. Immune modulation of renal inflammatory disease;105 8.4.10;10. Summary;106 8.4.11;Key points;106 8.4.12;References;106 8.5;Chapter 5. Pathogenesis of Renal Diseases: Renal Cell Response to Injury;110 8.5.1;1. Introduction;110 8.5.2;2. Formation of reactive oxygen species and nitric oxide are key determinants of renal tissue damage;110 8.5.3;3. Immune-mediated renal injury and the TLR system of innate immunity;111 8.5.4;4. Renal cell response to metabolic injury;117 8.5.5;Key points;121 8.5.6;References;121 8.6;Chapter 6. Renal Toxicities Associated with Immunomodulatory Drugs;124 8.6.1;1. Introduction;124 8.6.2;2. Drug effects and renal pathology;125 8.6.3;3. Individual drugs;126 8.6.4;4. Conclusions;133 8.6.5;Key points;134 8.6.6;Acknowledgments;134 8.6.7;References;134 9;Part III: The Vasculitides;138 9.1;Chapter 7. ANCA-Associated Systemic Vasculitides: Mechanisms;140 9.1.1;1. Introduction;140 9.1.2;2. ANCA and the idiopathic small-vessel vasculitides: clinical correlates;141 9.1.3;3. ANCA and the small-vessel vasculitides: in vitro evidence for pathogenicity;144 9.1.4;4. Pathogenicity of ANCA: in vivo experimental evidence;147 9.1.5;5. Pathogenesis of ANCA-associated small-vessel vasculitis: contribution of cell-mediated immunity;151 9.1.6;6. Conclusions;151 9.1.7;Key points;152 9.1.8;References;152 9.2;Chapter 8. ANCA-Associated Vasculitis: Clinical Features and Treatment;156 9.2.1;1. Introduction;156 9.2.2;2. Clinical features;159 9.2.3;3. Treatment;164 9.2.4;4. Summary;170 9.2.5;Key points;170 9.2.6;References;170 9.3;Chapter 9. Large and Medium Vessel Vasculitis: Mechanisms;176 9.3.1;1. Introduction;176 9.3.2;2. Takayasus arteritis: pathogenesis;176 9.3.3;3. Giant cell arteritis: pathogenesis;177 9.3.4;Key points;188 9.3.5;References;188 9.4;Chapter 10. Large and Medium Vessel Vasculitis: Clinical Features and Treatment;192 9.4.1;1. Introduction;192 9.4.2;2. Takayasus arteritis;193 9.4.3;3. Giant c
ell arteritis;197 9.4.4;4. Cogans syndrome;198 9.4.5;5. Sarcoid vasculitis;199 9.4.6;6. Behçets disease;200 9.4.7;7. Polyarteritis nodosa;201 9.4.8;8. Kawasakis disease;203 9.4.9;9. Conclusions;204 9.4.10;Key points;205 9.4.11;References;205 9.5;Chapter 11. Anti-GBM Disease: Mechanisms, Clinical Features, and Treatment;212 9.5.1;1. Introduction;212 9.5.2;2. Epidemiology;212 9.5.3;3. Clinical features;213 9.5.4;4. Diagnosis;215 9.5.5;5. Mechanisms;217 9.5.6;6. Mechanisms of injury;221 9.5.7;7. Genetic influences;222 9.5.8;8. Treatment;223 9.5.9;9. Future treatments;225 9.5.10;10. Transplantation in Goodpastures disease and Alports syndrome;226 9.5.11;Key points;227 9.5.12;References;227 9.6;Chapter 12. Renal Disease in Cryoglobulinemic Vasculitis;232 9.6.1;1. Introduction;232 9.6.2;2. Detection and identification of circulating cryoglobulins;234 9.6.3;3. Renal disease in mixed (type II) cryoglobulinemia;234 9.6.4;4. Renal disease in type I cryoglobulinemia;245 9.6.5;Key points;252 9.6.6;Acknowledgments;253 9.6.7;References;253 9.7;Chapter 13. Henoch-Schönlein Purpura;258 9.7.1;1. Introduction and definition;258 9.7.2;2. Epidemiology, pathophysiology, and genetic influence;258 9.7.3;3. Clinical features;259 9.7.4;4. Laboratory findings;262 9.7.5;5. Histology;263 9.7.6;6. Diagnosis;265 9.7.7;7. Treatment;266 9.7.8;8. Clinical course, and outcome;268 9.7.9;9. Conclusions;269 9.7.10;Key points;269 9.7.11;References;269 9.8;Chapter 14. Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura;274 9.8.1;1. Stx-associated HUS;274 9.8.2;2. Atypical HUS (aHUS, alias non-Stx-HUS);279 9.8.3;3. Thrombotic thrombocytopenic purpura;284 9.8.4;Key points;292 9.8.5;Acknowledgments;292 9.8.6;References;292 10;Part IV: The Connective Tissue Diseases;300 10.1;Chapter 15. Systemic Lupus Erythematosus: Mechanisms;302 10.1.1;1. Introduction;302 10.1.2;2. Genetic, environmental, and hormonal factors in SLE;302 10.1.3;3. Mechanisms of disease;305 10.1.4;4. Conclusion;318 10.1.5;Key point
s;319 10.1.6;References;319 10.2;Chapter 16. Systemic Lupus Erythematosus: Renal Involvement;328 10.2.1;1. Introduction;328 10.2.2;2. Renal pathologic changes;328 10.2.3;3. The renal biopsy in SLE: practical considerations;337 10.2.4;Key points;338 10.2.5;References;338 10.3;Chapter 17. Systemic Lupus Erythematosus: Treatment;340 10.3.1;1. Introduction;340 10.3.2;2. Induction therapy with cyclophosphamide;341 10.3.3;3. Induction therapy with mycophenolate mofetil;342 10.3.4;4. Maintenance therapy;343 10.3.5;5. Newer therapies;344 10.3.6;6. Membranous lupus nephritis (MLN);346 10.3.7;7. Adjunctive therapy;347 10.3.8;8. Conclusion;347 10.3.9;Key points;347 10.3.10;Acknowledgment;347 10.3.11;References;347 10.4;Chapter 18. The Antiphospholipid Syndrome;350 10.4.1;1. Introduction;350 10.4.2;2. Laboratory diagnosis;350 10.4.3;3. Risk factors for thrombosis in APS: two hit hypothesis;352 10.4.4;4. Conditions associated with APS;353 10.4.5;5. Organ manifestations of APS;353 10.4.6;6. Renal manifestations;354 10.4.7;7. Hypertension;354 10.4.8;8. Renal artery lesions;355 10.4.9;9. Cortical ischaemia/infarction;356 10.4.10;10. Thrombotic microangiopathy;356 10.4.11;11. Renal vein and inferior vena cava thrombosis;357 10.4.12;12. End-stage renal failure and renal transplantation;357 10.4.13;13. Treatment;358 10.4.14;14. Summary;360 10.4.15;Key points;361 10.4.16;References;361 10.5;Chapter 19. Renal Involvement in Sjögren Syndrome;366 10.5.1;1. Introduction;366 10.5.2;2. Interstitial nephritis;368 10.5.3;3. Glomerulonephritis;371 10.5.4;4. Predictors of renal involvement and associations with other characteristics of pSS;373 10.5.5;5. Treatment;374 10.5.6;6. Conclusions;375 10.5.7;Key points;375 10.5.8;Acknowledgments;376 10.5.9;References;376 10.6;Chapter 20. The Kidney in Systemic Sclerosis;380 10.6.1;1. Pathogenesis of renal involvement;380 10.6.2;2. Renal pathology;383 10.6.3;3. Renal crisis demographics;384 10.6.4;4. Laboratory findings;388 10.6.5;5. Management;389 10.6.6
;6. Non-renal crisis kidney problems;393 10.6.7;Key points;395 10.6.8;References;395 10.7;Chapter 21. Amyloidosis;400 10.7.1;1. Introduction;400 10.7.2;2. Pathogenesis of amyloidosis;400 10.7.3;3. Clinical amyloidosis;401 10.7.4;4. Diagnosis of amyloidosis;406 10.7.5;5. Management of amyloidosis;409 10.7.6;Key points;411 10.7.7;Acknowledgments;412 10.7.8;References;412 10.8;Chapter 22. Inflammatory Arthritis, Behçets Syndrome, and Sarcoidosis;414 10.8.1;1. Introduction;414 10.8.2;2. Inflammatory arthritis;414 10.8.3;3. Sarcoidosis;417 10.8.4;4. Behçets disease;420 10.8.5;Key points;421 10.8.6;References;422 11;Index;424